Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Chardan Capital

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a research report issued on Thursday,Benzinga reports. They presently have a $7.00 target price on the stock. Chardan Capital’s target price would indicate a potential upside of 239.81% from the company’s current price.

Several other equities analysts also recently weighed in on the company. Canaccord Genuity Group reduced their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Stock Down 9.3 %

TSHA opened at $2.06 on Thursday. The business’s fifty day simple moving average is $1.98 and its 200 day simple moving average is $2.38. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32. The firm has a market cap of $422.18 million, a P/E ratio of 3.27 and a beta of 0.44. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.35.

Institutional Investors Weigh In On Taysha Gene Therapies

Several hedge funds have recently modified their holdings of TSHA. Avoro Capital Advisors LLC grew its stake in Taysha Gene Therapies by 328.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after purchasing an additional 14,294,445 shares in the last quarter. StemPoint Capital LP acquired a new stake in Taysha Gene Therapies during the 1st quarter valued at approximately $3,122,000. Wellington Management Group LLP acquired a new stake in Taysha Gene Therapies during the 3rd quarter valued at approximately $931,000. Bank of New York Mellon Corp acquired a new stake in Taysha Gene Therapies during the 2nd quarter valued at approximately $1,018,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Taysha Gene Therapies during the 3rd quarter valued at approximately $416,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.